Boston Scientific earnings: CRM slump continues as BSX swings to a loss in Q2, lowers guidance for 2012

July 26, 2012 by MassDevice staff

Boston Scientific takes a non-cash $3.4 billion impairment of goodwill charge to its bottom line over weakening economic conditions, sending the medical device company to a loss for the quarter; DES, CRM and ICD sales slump badly in the quarter as 2012 outlook lowered.


Boston Scientific (NYSE:BSX) swung to a $3.4 billion loss, lowered its year-end guidance and saw its bread and butter businesses drop by double-digit percentage points during a tough 2nd quarter for the medical device company.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.